[1] Salinas S, Proukakis C, Crosby A, et al.Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms[J]. Lancet Neurol, 2008, 7(12): 1127-1138. [2] 林鹏飞,龚瑶琴,焉传祝. 遗传性痉挛性截瘫的分子遗传学研究进展[J]. 中华神经科杂志, 2015, 48(11): 1030-1038. [3] Kang SY, Lee MH, Lee SK, et al.Levodopa-responsive parkinsonism in hereditary spastic paraplegia with thin corpus callosum[J]. Parkinsonism Relat Disord, 2004, 10(7): 425-427. [4] Anheim M, Lagier-Tourenne C, Stevanin G, et al.SPG11 spastic paraplegia. A new cause of juvenile parkinsonism[J]. J Neurol, 2009, 256(1): 104-108. [5] Paisan-Ruiz C, Guevara R, Federoff M, et al.Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations[J]. Mov Disord, 2010, 25(12): 1791-1800. [6] Guidubaldi A, Piano C, Santorelli FM, et al.Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa-responsive Parkinsonism[J]. Mov Disord, 2011, 26(3): 553-556. [7] Ramirez-Zamora A, Gee L, Youn Y, et al.Pallidal deep brain stimulation for the treatment of levodopa-responsive juvenile dystonia and parkinsonism secondary to SPG11 mutation[J]. JAMA Neurol, 2017, 74(1): 127-128. [8] Stevanin G, Santorelli FM, Azzedine H, et al.Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum[J]. Nat Genet, 2007, 39(3): 366-372. [9] Stevanin G, Montagna G, Azzedine H, et al.Spastic paraplegia with thin corpus callosum: Description of 20 new families, refinement of the SPG11 locus, candidate gene analysis and evidence of genetic heterogeneity[J]. Neurogenetics, 2006, 7(3): 149-156. [10] Hehr U, Bauer P, Winner B, et al.Long-term course and mutational spectrum of spatacsin-linked spastic paraplegia[J]. Ann Neurol, 2007, 62(6): 656-665. [11] Coutinho P, Barros J, Zemmouri R, et al.Clinical heterogeneity of autosomal recessive spastic paraplegias: Analysis of 106 patients in 46 families[J]. Arch Neurol, 1999, 56(8): 943-949. [12] Simpson MA, Cross H, Proukakis C, et al.Maspardin is mutated in mast syndrome, a complicated form of hereditary spastic paraplegia associated with dementia[J]. Am J Hum Genet, 2003, 73(5): 1147-1156. [13] Orlacchio A, Kawarai T, Totaro A, et al.Hereditary spastic paraplegia: clinical genetic study of 15 families[J]. Arch Neurol, 2004, 61(6): 849-855. [14] Okubo S, Ueda M, Kamiya T, et al.Neurological and neuroradiological progression in hereditary spastic paraplegia with a thin corpus callosum[J]. Acta Neurol Scand, 2000, 102(3): 196-199. [15] Davison C.Pallido-pyramidal disease[J]. J Neuropathol Exp Neurol, 1954, 13(1): 50-59. [16] Tranchant C, Koob M, Anheim M.Parkinsonian-pyramidal syndromes: a systematic review[J]. Parkinsonism Relat Disord, 2017, 39: 4-16. [17] Park JS, Blair NF, Sue CM.The role of ATP13A2 in Parkinson's disease: clinical phenotypes and molecular mechanisms[J]. Mov Disord, 2015, 30(6): 770-779. [18] Yoshino H, Tomiyama H, Tachibana N, et al.Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism[J]. Neurology, 2010, 75(15): 1356-1361. [19] Di Fonzo A, Dekker MC, Montagna P, et al.FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome[J]. Neurology, 2009, 72(3): 240-245. [20] Wijemanne S, Jankovic J.Dopa-responsive dystonia–clinical and genetic heterogeneity[J]. Nat Rev Neurol, 2015, 11(7): 414-424. [21] Bandmann O, Weiss KH, Kaler SG.Wilson's disease and other neurological copper disorders[J]. Lancet Neurol, 2015, 14(1): 103-113. [22] Machado A, Chien HF, Deguti MM, et al.Neurological manifestations in Wilson's disease: Report of 119 cases[J]. Mov Disord, 2006, 21(12): 2192-2196. [23] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 脑组织铁沉积神经变性病诊治专家共识[J]. 中华医学杂志, 2016, 96(27): 2126-2133. [24] Schneider SA, Hardy J, Bhatia KP.Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations[J]. Mov Disord, 2012, 27(1): 42-53. [25] Thomas M, Hayflick SJ, Jankovic J.Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration[J]. Mov Disord, 2004, 19(1): 36-42. |